semaglutide glp-1 peptide | GLP-1R Ligand | Sterile | CAS #910463-68-2 semaglutide [TUSOM | Pharmwiki]

Tirzepatide tends to produce greater average weight loss in clinical trials

Most patients notice appetite suppression during their first week, though visible weight loss typically emerges between weeks two and four

The Phase 2 trial data confirms this: the 1mg dose group achieved only 8.7% weight loss at 48 weeks, indicating that low doses produce modest effects that accumulate slowly

Most patients find that staying at one consistent dose produces better long-term adherence and fewer side effects than constantly increasing amounts

MRI and Imaging Data: Structural brain MRI may be required to rule out central causes such as acoustic neuroma or demyelinating disease